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Abstract  
Catecholaminergic polymorphic ventricular tachycardia 
(CPVT) is induced by stress or exertion especially in young 
individuals with normal baseline ECG and without any structural 
heart disease. The most common type of ventricular tachycardia 
(VT) in these patients is bidirectional VT but could also be 
polymorphic VT or ventricular fibrillation. These two main 
types of CPVT are caused by mutations on the ryanodine (RyR2) 
or calsequestrin (CASQ2) receptor, with an autosomal dominant 
and recessive inheritance pattern respectively. The prognosis is 
dismal without treatment and the main therapeutic approach 
consists of administration of beta blocker, flecainide, calcium 
channel blockers or ICD implantation. Genetic testing is 
important for all family members of CPVT probands in order to 
identify asymptomatic carriers. Rhythmos 2018;13(1):6-8.   
Keywords: catecholaminergic polymorphic ventricular tachycardia; 
sudden cardiac death; genetic testing; channelopathies  
Abbreviations: CASQ2 = calsequestrin receptor, CPVT = 
catecholaminergic polymorphic ventricular tachycardia, DADs = 
delayed after – depolarizations, ICD = implantable cardiac defibrillator, 
RyR2 = ryanodine receptor, SCD = sudden cardiac death 
 
Introduction  
Catecholaminergic polymorphic ventricular tachy-
cardia (CPVT) is a rare inherited potentially lethal cardiac 
arrhythmia, first described by Reid in 1975 and more syste-
matically by Coumel in 1978.1,2 It is induced by emotional 
stress or exercise usually during the first or second decade 
of life in patients without structural heart disease and may 
be either polymorphic or bidirectional ventricular tachy-
cardia (VT) or ventricular fibrillation (Fig. 1). Common 
clinical manifestations of CPVT are syncope or sudden 
cardiac death (SCD). 3  
Genetic basis of CPVT  
About 5 types of CPVT have been described, but the 
most common type accounting for 50-60% of the cases in 
an autosomal dominant form, is caused by a mutation on 
the hRyR2 gene that encodes for the cardiac ryanodine 
receptor (RyR2). The RyR2 is involved in the regulation 
of cardiac calcium (Ca+2) homeostasis controlling its 
release from the sarcoplasmic reticulum to the cytosol in 
response to the Ca+2 entry during the plateau phase of the 
action potential.4 The second most common type of CPVT 
is caused by a mutation on the CASQ2 gene, encoding for 
calsequestrin and the rate of SCD is higher than that 
observed in the first type.5 Mutations on the KCNJ2 gene 
have been described in individuals presented with exercise 
induced bidirectional VT without QTc prolongation. These 
patients do not have the phenotypic abnormalities related 
to Andersen-Tawil syndrome which is also caused by 
mutations in the same gene.6,7 
 Figure 1. Clinical and ECG types of catecholaminergic 
polymorphic ventricular tachycardia (CPVT), A: Polymorphic 
VT, B: Bidirectional VT, C: Ventricular Fibrillation  
Natural history and clinical presentation 
The prevalence of CPVT is estimated ~1:10,000 but 
due to the nature of the syndrome it is not easy to know the 
exact prevalence since the first clinical presentation could 
be SCD.2 CPVT is a familial cardiac arrhythmia and about 
30% of probands have a family history of SCD before the 
age of 40 years.8 Patients have their first symptoms in early 
childhood but the mean age of the onset of syncope is 12 
years.9 The resting ECG and the echocardiogram are 
usually normal and patients have syncopal episodes during 
stress which could be easily ascribed to neurologic 
disorders. Thus, diagnosis is usually delayed which may 
lead to a fatal outcome. Some patients have sinus brady-
cardia or prominent U waves in the resting ECG. 
Bradycardia may be due to the impaired handling of Ca+2 
by the mutant RyR2 channel in the sinoatrial nodal cells.10 
Also, in some cases a mild prolongation of the QT interval 
has been reported, thus implicating long QT syndrome in 
the differential diagnosis of the syncope. 11,12 
The most important clinical test to diagnose CPVT is 
the exercise stress test and this should be performed in all 
patients with adrenergically driven – syncope. The typical 
pattern consists of the appearance of premature ventricular 
beats, isolated or in couplets, usually polymorphic, when 
the heart rate is >100 bpm followed by runs of VT at upper 
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heart rate values.8,13 As mentioned above, the tachycardia 
could be either polymorphic or bidirectional which is the 
typical characteristic pattern of CPVT. Bidirectional VT is 
characterized by an 1800 beat to beat change of the frontal 
QRS axis and is caused by delayed after – depolarizations 
(DADs) – induced triggered activity due to excessive Ca+2 
diastolic release.8,14 Although this pattern is typical for the 
majority of patients, CPVT could also be manifested either 
as polymorphic VT or ventricular fibrillation (VF).8 
Additionally, supraventricular tachyarrhythmias may 
occur in patients with CPVT. Sustained or non – sustained 
atrial tachycardias and atrial fibrillation are sometimes 
observed during exercise. The Ca+2 overload caused by 
those supraventricular tachycardias could in turn promote 
triggered activity in the ventricle.15 It must be noted that 
the origin of CPVT VTs could be in the right and/or left 
ventricular outflow tract area or even at the right 
ventricular apex, suggesting a multifocal origin.16  
Exercise testing remains the cornerstone of clinical 
tools to reproduce the VT patterns of CPVT. VT is not 
inducible during an electrophysiology study with 
programmed ventricular stimulation, and such study does 
not have any prognostic value. Contrariwise, heart rhythm 
monitoring, either with ambulatory Holter recording or 
with implantable loop recorders, is very useful to diagnose 
CPVT especially in patients with emotional stress. 17  
Management of patients with CPVT 
The mortality rate for untreated individuals with 
CPVT may reach 50% by 20 years of age.11 Current 
treatment includes curtailed exercise, avoidance of 
stressful situations, and β-blocker therapy. Beta blockers, 
and specifically those without intrinsic sympathomimetic 
activity, are considered the first line treatment option in 
patients with CPVT.17 The recommended beta blocker is 
nadolol, which is a long-acting drug, at a dose of 1-2 
mg/kg.2 Propranolol is an alternative beta blocker since 
nadolol is not available in several countries. Dosage 
titration and follow up with beta blocker therapy require 
repeated exercise tests and Holter recordings. The annual 
rate of arrhythmic events on beta-blockers ranges between 
3% and 11% per year.18 In the Italian CPVT registry ~30% 
of patients had recurrent arrhythmia episodes treated with 
the maximal tolerated dose of beta blockers.8,19  
Flecainide seems to have a beneficial effect in the 
suppression of ventricular arrhythmia events and it was 
initially tested in a CASQ2 knock-out mouse model.20 The 
exact mechanism is not yet clearly defined and small case 
series have been reported. Flecainide add-on therapy in 
patients already receiving beta blocker without complete 
suppression of ventricular arrhythmias is recommended.17 
According to a first small randomized cross-over study, in 
13 patients with CPVT receiving background beta-blocker 
therapy and fitted with an implantable cardioverter 
defibrillator (ICD), the median ventricular arrhythmia 
score during exercise was significantly reduced by 
flecainide (0 vs 2.5 for placebo; P < .01), with complete 
suppression observed in 11 of 13 patients (85%) with no 
difference in the overall and serious adverse events 
between the flecainide and placebo arms. 21   
In addition to medical therapy, an ICD should be 
implanted in patients with aborted SCD. Painful ICD 
shocks can increase sympathetic tone leading to electrical 
storm and repeated ICD discharges which could be 
potentially fatal. Hence, it is crucial to carefully program 
the ICD parameters with long delays and high cut off rates 
taking also into account the high incidence of supra-
ventricular arrhythmias in these patients.22,23 In a 2-year 
follow up ~50% of patients with implanted ICD received 
appropriate therapy despite medical therapy. Also, in the 
same cohort, patients without secondary prevention 
indication also received appropriate ICD discharges.19 
Calcium channel blockers, mainly verapamil, have 
also been studied in patients with CPVT.24 Rosso et al 
reported a reduction in the arrhythmic events in patients 
who received verapamil plus beta blocker.25 
Left cervical sympathectomy is indicated for patients 
in whom beta blockers are contraindicated or cases with an 
ICD who continue having recurrent VT episodes despite 
maximal drug therapy.26 Nevertheless, this therapy should 
not be considered as an alternative to ICD implantation as 
it has not proved the elimination of ventricular arrhythmias 
during long-term follow up. Moreover, it requires well 
trained surgeons in order to avoid complications, like 
Horner syndrome which is rare in experienced centers.27 
Screening is useful for patients who suffer from CPVT 
and their family members. Both clinical evaluation and 
genetic testing are required to identify undiagnosed and 
asymptomatic family members in the presence of CPVT 
probands. To date, over 130 mutations have been reported 
showing a high degree of genetic heterogeneity.28 The 
autosomal dominant variant, which is related to RyR2 
mutations, is by far more frequent (50%-55% of patients 
with CPVT).4 Because RyR2 is one of the largest genes in 
the human genome, with 105 exons, many laboratories 
have limited the test only on selected regions (about 66 
exons) which have been related to CPVT, with a lower 
detection sensitivity.29 Screening should be performed in 
all definitive CPVT probands and considered in subjects 
with idiopathic VF when an adrenergic trigger is 
identified. On the other hand, screening for CASQ2 
mutation concerns subjects in whom a recessive pattern of 
inheritance has been observed or when the RyR2 screening 
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is negative. In total, the yield of genetic testing is about 55 
– 60% and when clinical diagnosis is clear it shows a good 
cost – effectiveness ratio.30 
New modes of therapy, such as gene therapy for CPVT 
caused by CASQ2 loss-of-function variants,31 are currently 
being explored and may hopefully become available in the 
future for this potentially lethal form of inherited 
channelopathy.  
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